A total of eight pan-RAS inhibitors from Chinese firms are currently being developed in preclinical or early-stage clinical studies, with the most advanced, Genfleet's GFH276, set to read out Phase I results during ESMO in October.
A total of eight pan-RAS inhibitors from Chinese firms are currently being developed in preclinical or early-stage clinical studies, with the most advanced, Genfleet's GFH276, set to read out Phase I results during ESMO in October.